Introduction
============

Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths global, which is the fifth most common malignancy and the third leading cause of cancer-related death [@B1]. As with many cancers, HCC in early stage has better prognosis compared to advanced stage disease [@B1], [@B2]. Despite imaging technology has greatly improved the detection of HCC; biochemical analyses are still indispensable for its diagnosis, especially for the early stage of disease. Alpha fetal protein (AFP) is still the only available blood test for detection and surveillance of HCC; However, is limited by its poor sensitivity and has proven to be a less than ideal surrogate for monitoring treatment response of HCC [@B3], such as elevated serum AFP was only observed in 60-70% of overall HCC patients, while the proportion was merely 33-65% regarding patients harboring HCCs of \<3 cm in diameter [@B4], [@B5]. Therefore, inefficient diagnosis of early stage HCC remains a primary causal factor of the high mortality and poor prognosis.

Biochemical parameters of liver function test (LFT) is responsible for metabolism and excretion of various endogenous and foreign substances[@B6].In patients with liver-specific diseases, accurate assessment of liver function is critical for the selection of treatment options. Hepatitis and cirrhosis, for example, are associated with an increased risk of liver failure after partial liver resection, especially after neo-adjuvant chemotherapy, or in living donor liver transplantation [@B7].

Currently, the American Joint Committee on Cancer (AJCC) TNM classification, based on pathological information, and the treatment regimens for HCC patients were established according to the staging system [@B8]. Large variations are reported in the clinical outcomes, even patients with the same stage receiving similar treatment strategies [@B9].This findings indicate that the present staging system is inadequate for predicting recurrence and does not reflect the biological heterogeneity of HCC patients. However, many other risk factors, such as age, sex, alcohol status, body mass index (BMI), HBs Ag, LFT, coagulation tests have been demonstrated to influence recurrence in HCC patients [@B10] and should be considered for predicting individualized prognosis, the same as the AFP-negative HCC. Therefore, a comprehensive, easy-to-use tool that estimates individual risk by incorporating TNM stage and LFT factors could serve as a valuable decision-making tool for clinicians.

Therefore, the aim of our study was to develop and validate a nomogram that combined both clinicopathologic factors, LFT factors and other tumor markers for the prognosis in patients with AFP-negative HCC [@B11]-[@B13]. We also performed a test to determine whether this model provides a more accurate prediction of prognosis when compared with TNM staging systems [@B14].

Methods
=======

Patient selection
-----------------

The primary cohort of our study comprised 419 patients with histologically diagnosed HCC who were retrospectively reviewed from the information system from April 2008 to April 2014. All the patients had undergone surgical resection with curative intent. Only the first records of hospitalizations were retained, and the levels of LFT factors and tumor markers were investigated before treatment. However, cases with concomitant diseases which might influence serum LFT levels (i.e., diabetes, hyperlipidemia, or metabolic syndrome) were excluded. In addition, patients with other types of tumors were also excluded. The stage of tumor was evaluated using the American Joint Committee on Cancer Staging system (AJCC, 2002; Greene). From April 2014 to January 2015, 150 consecutive patients were enrolled in independent validation cohort using the same inclusion and exclusion criteria as that in the primary cohort. The patients in the validation cohort were restaged according to the seventh AJCC TNM staging manual. The study was approved by the ethics committees in Sun Yat-sen University Cancer Center (SYSUCC, Guangdong, China). It was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. The authenticity of this article has been validated by uploading the raw data onto the Research Data Deposit public platform (<http://www.researchdata.org.cn>), with the approval RDD Number as RDDA2018000808.

Laboratory Measurements
-----------------------

Patients received routine tests at the first visit in our hospital. Serum samples were collected and clotted at room temperature, then centrifuged at 3500 r/min for 10 min, which could be used to estimate the level of serum biomarkers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), lactate dehydrogenase (LDH), gamma-glutamyl transpeptidase (GGT), albumin (ALB), carcino-embryonic antigen (CEA) and CA199. The Baseline clinical data, including age, gender, preoperative histologic grade, and HBV infection were extracted from the Electronic Medical Record (EMR) system. Informed consent was obtained from each patient prior to use of serum and plasma. All patients provided written informed consent. The Institute Research Ethics Committee of the Sun Yat-Sen University Cancer Center, Guangzhou, China approved this study.

Follow-up
---------

All HCC patients were advised to receive regular follow-ups after completion of the primary therapy according to clinical guidelines. Patients were generally followed up every 3 months in the first 2 years and annually thereafter for patients without evidence of recurrence in the following 3 to 5 years. Patients who did not visit our hospital as scheduled were telephoned for follow-ups to obtain the treatment information and living status (performed by The Medical Information Unit in our Cancer Center). The last follow-up occurred in June 2016. The outcome of our study was overall survival (OS). OS was defined as the time from the diagnosis of HCC to the date of the last follow-up or death.

Statistical analysis
--------------------

Statistical analysis was done using SPSS 16.0 (IBM, Chicago, IL, USA) and R software (version 3.1.4; <http://www.Rproject.org>). Categorical variables were classified based on clinical findings. All the optimal cut-off points in our study were evaluated by reference ranges and continuous variables were transformed to categorical variables. Univariate and multivariate regression analysis was used to analyze the risk factors, to predict prognosis selected for the derivation of prediction models.

Risk factors which based on the multivariable logistic analysis were applied to develop a diagnostic model for AFP-negative HCC by using the primary cohort[@B15]. Backward step down selection was performed as the final stopping rule with the Akaike information criterion. The nomogram was constructed for predicting 3 and 5years OS. Nomogram validation consisted of discrimination and calibration by using the primary and validation set. To quantify the discrimination performance of the nomogram, Harrell\'s C-index was evaluated. In brief, a C-index value greater than 0.75 is considered to represent relatively good discrimination. Calibration was performed by observing survival probability with Kaplan-Meier estimating. In the validation cohort, according to the established nomogram, the C-index and calibration curve were derived based on the regression analysis. The decision curve was also plotted for the model of nomogram and TNM staging system [@B16], [@B17]. The total points of each patient were calculated according to the established Cox regression model, 2 groups of patients with high and low risk of prognosis (based on the total points) were delineated using maximally selected rank statistics as implemented in the maxstat package. Survival curves were depicted by the Kaplan-Meier method, and using the dichotomized risk group as a factor, finally, compared using the log-rank test. A two tailed P value \< 0.05 was considered statistically significant.

Results
=======

Basic characteristics
---------------------

For nomogram construction and validation, we assigned three quarters of the patients to the primary set and one quarter to the validation set. The clinic pathologic characteristics of the training and validation sets were evaluated. The characteristics of the 419 consecutive AFP-negative HCC patients in the primary cohort and 150 patients in the validation cohort are showed in Table [1](#T1){ref-type="table"}. For the primary cohorts, there were 105 patients died in cancer for 5 years.

Biomarker Selection
-------------------

All the available information\'s, including clinic pathologic characteristics and biomarkers, were included for univariate and multivariate analysis (Table [2](#T2){ref-type="table"}). In univariate analyses, there were significant correlation between BMI, TNM stage, tumor stage, node stage, and distant metastases, HBs Ag, AST, LDH, GGT, ALB, PT, CEA, CA199 and OS. The multivariate analyses were then performed to identify factors distinguished in univariate analyses. Result showed that BMI, tumor stage, distant metastases, HBs Ag, LDH, GGT and ALB, were independent risk factors for prognosis of AFP-negative HCC.

Development and Validation of the Prediction Model
--------------------------------------------------

A nomogram was constructed to predict 3- and 5- year OS, on the basis of the identified prognostic factors (Figure [1](#F1){ref-type="fig"}). The validation of nomogram was consisted of discrimination and calibration by using the validation set. Discrimination was performed by using a concordance index (C-index) and ROC curves. Calibration was evaluated by comparing the means of predicted survival with estimating of predicted with observed Kaplan-Meier survival, with the x-axes are actual survival estimated by the nomogram, the y-axes are observed survival calculated by the Kaplan-Meier method. The C-index for OS prediction was 0.807 (95% CI: 0.770-0.844). The AUC (ROC curve) was 0.809(95%CI: 0.762-0.857), with sensitivity 85.00%, specificity 68.00%, PPV 48% and NPV 93% (Figure [2](#F2){ref-type="fig"}A). The calibration plot for the probability of OS at 3 or 5 year after therapy showed an optimal agreement between the prediction by nomogram and actual observation (Figure [3](#F3){ref-type="fig"}).

Validation of the Predictive Accuracy of Nomograms for OS
---------------------------------------------------------

In the validation cohort, The C-index for OS prediction was up to 0.866 (95% CI: 0.796-0.936). The AUC was 0.832 (95%CI: 0.747-0.917), with sensitivity 89.50%, specificity 68.00%, PPV 30.00% and NPV 98.00% (Figure [2](#F2){ref-type="fig"}B). The calibration plot for the probability of OS at 3- year after therapy showed an optimal agreement between the prediction by nomogram and actual observation (Figure [3](#F3){ref-type="fig"}).

Decision curve analysis
-----------------------

The decision curve analysis for the nomogram and TNM staging systems is showed in Figure [4](#F4){ref-type="fig"}. The decision curve presented that if the threshold probability of a patient is \> 10%, the developed nomogram and TNM staging system in predicting OS is more benefit than all patients dead scheme or none patients dead scheme. Furthermore, the net benefit was comparable; the nomogram in predicting OS is more benefit than that of TNM staging system in this range.

Comparison of Predictive Accuracy for OS Between Nomogram and TNM Stage Systems
-------------------------------------------------------------------------------

Based on the nomogram we developed in this study, patients were subdivided into a low-risk group, and a high-risk group, which showed good prognostic classification for HCC patients both in primary cohort and validation cohort. In the primary cohort, there were 232 patients in the low-risk group, 89 patients in the middle-risk group, while 73 patients in the high-risk group. The OS between the 3 risk groups were (37.76 ± 14.44) months, (31.39 ± 17.93) and (25.63 ± 18.82) months (p \< 0.001). Also, in the validation cohort, there were 121 patients in the low-risk group, 17 patients in the middle-risk group, while 6 patients in the high-risk group. The OS between the 3 risk groups were (22.45 ± 8.96) months, (14.59 ± 9.19) months and (9.83 ± 10.18) months (p \<0.001) (Figure [5](#F5){ref-type="fig"}).

Furthermore, the discrimination of the nomogram and that of the AJCC TNM Stage have been compared. In the primary cohort, the C-index of nomogram was 0.807 (95% CI: 0.770-0.844), which was superior than the C-index of AJCC TNM Stage(0.697, 95% CI: 0.649-0.745, P \< 0.001),or that of other biomarkers (Table [3](#T3){ref-type="table"}).

Discussion
==========

The accurate tumor prognosis after definitive treatment is important. Based on the conventional TNM stage system, there are varies controversies, that the system only take the anatomical extent of the disease into account and not think about the liver biological function heterogeneity of AFP-negative HCC, which could not completely reflect the accurate prognosis. Nomograms have been developed and shown to be more accurate than the conventional staging systems for predicting prognosis in some cancers [@B18]-[@B20]. Thus, we planned to develop and validate a prognostic nomogram, which included serum/plasma liver biological function biomarker, had better predictive accuracy than those of the traditional TNM stage system.

For construction of the nomogram, clinic pathologic factors, biomarkers into the TNM staging system and liver biological function have been examined by Multivariate analysis [@B21]. This method could choose the predictors for the OS of AFP-negative HCC. The nomogram were combined with tumor stage, metastasis stage, BMI, LDH level, GGT level, ALB level and HBs Ag status. The nomogram performed well in predicting overall survival, which showed adequate discrimination in the primary cohort (C-index, 0.807; AUC: 0.809), which was then surprisingly improved in the validation cohort (C-index, 0.866; AUC: 0.832). When compared with the conventional TNM stage system(C-index, 0.697,*P* \< 0.01) or other biomarkers, the nomogram showed better predictive accuracy for OS. Furthermore, both in primary cohorts and validation cohort, patients were divided into three distinct risk groups for OS based on the nomogram, which could effectively discriminate the survival outcomes. Thus, the nomogram, which composed of the clinical and biomarkers we already have, could be used to a more convenient biomarker for the prediction of OS and treatment strategies guidance for AFP-negative HCC [@B22], [@B23].

AFP is the best tumour marker of HCC, and it is used for the clinical diagnosis of liver cancer screening, prognostic judgement and recurrence monitoring [@B24]. However, recent studies reported that the sensitivity of AFP for the diagnosis of HCC is only 40-65%, and the specificity is 76-96%. Notably, AFP expression in many cases of liver cancer is not elevated or even expressed [@B25]. Our studies have intended to identify a diagnostic factor for AFP-negative HCC.

TNM stage system is the most common staging system of HCC, which is composed of tumor stage, node stage and metastasis stage, could be served as treatment guideline and the independent risk factor for the prognosis of AFP [@B26]. Unexpectedly, the prognosis of HCC is not only related to tumor factors (TNM stage), but also to the liver function of patients, only the integration of TNM stage may introduce sampling bias to the treatment and the prognosis [@B26]. Therefore, we recommended that the TNM stage integrate LFTs for the OS prediction. In this study, tumor diameter and tumor number (tumor stage, C-index, 0.701) which reflected the invasiveness of HCC, were significantly associated with prognosis on multivariate analysis. Furthermore, the tumor metastasis was a strong risk factor(C-index, 0.529). The prognosis of the patients with tumor metastasis was significantly poorer. The LFTs, including LDH (C-index, 0.630), GGT (C-index, 0.649) and ALB (C-index, 0.574) have been suggested to be independent risk factors for prognosis of AFP-negative HCC. Furthermore, the basic condition of patients, such as BMI (C-index, 0.560) and HBs Ag (C-index, 0.561) also included in the nomogram. But tumor markers have not been included in the nomogram. The decision curve showed that the nomogram in predicting OS is more benefit than that of TNM staging system in all range [@B28].

Several limitations in our study. First, the nomogram was established based on data obtained from one institution in China. Second, in the validation cohort the follow-up time was shorter, and close monitoring and five-year follow-up data are still required for patients in the validation cohort. The third limitation is more patients needed both in the primary and the validation cohort.

Conclusions
===========

In summary, we developed and validated nomograms to predict the three- and five-year OS for AFP-negative HCC. The proposed nomogram in this study provided statistically significantly better discrimination than the current TNM stage, and it offers a useful tool for prognosis. To generalize the use of this nomogram in other groups, additional validation with data from other institutions is required.
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###### 

Patient demographics and clinical characteristics

                     Primary cohort (419)   Validation cohort (150)   P value
  ------------------ ---------------------- ------------------------- ---------
  Age(Median)                                                         
  \<57               203(48.45%)            70(46.67%)                0.708
  ≥57                216(51.55%)            80(53.33%)                
  Sex                                                                 
  Male               374(89.26%)            135(90.00%)               0.800
  Female             45(10.74%)             15(10.00%)                
  OS status                                                           
  Survive            314(74.94%)            131(87.33%)               0.002
  Dead               105(25.06%)            19(12.67%)                
  DFS status                                                          
  Survive            310(73.99%)            129(86.00%)               0.003
  Dead/ recurrence   109(26.01%)            21(14%)                   
  BMI                                                                 
  \<18.5             39(9.31%)              14(3.34%)                 0.996
  18.5-25            280(66.83%)            98(23.39%)                
  ≥25                90(21.48%)             32(7.64%)                 
  Family history                                                      
  No                 329(78.52%)            119(79.33%)               0.872
  Yes                89(21.24%)             31(20.67%)                
  Alcohol                                                             
  No                 270(64.43%)            102(68.00%)               0.432
  Yes                149(35.56%)            48(32.00%)                
  ECOG                                                                
  0-1                412(98.33%)            144(96.00%)               0.101
  2                  7(1.67%)               6(4.00%)                  
  Clinical stage                                                      
  Ⅰ                  213(50.84%)            81(54.00%)                0.584
  Ⅱ                  86(20.53%)             25(16.67%)                
  Ⅲ-Ⅳ                120(28.64%)            44(29.33%)                
  Tumor stage                                                         
  T1                 216(51.55%)            82(54.67%)                0.522
  T2                 94(22.43%)             27(18.00%)                
  T3-T4              109(26.01%)            41(27.33%)                
  Node stage                                                          
  N0                 396(94.51%)            139(92.67%)               0.414
  N1                 23(5.49%)              11(7.33%)                 
  Metastasis stage                                                    
  M0                 401(95.70%)            143 (95.33%)              0.147
  M1                 18(4.30%)              7(4.67%)                  
  HBs Ag                                                              
  Negative           69(16.47%)             31(20.67%)                0.329
  Positive           335(79.95%)            119(79.33%)               
  AST(U/L)                                                            
  \<40               232(55.37%)            84(56.00%)                0.894
  ≥40                187(44.63%)            66(44.00%)                
  ALT(U/L)                                                            
  \<50               270(64.44%)            104(69.33%)               0.278
  ≥50                149(35.56%)            46(30.67%)                
  LDH(U/L)                                                            
  \<250              343(81.86%)            122(81.33%)               0.886
  ≥250               76(18.14%)             28(18.67%)                
  GGT(U/L)                                                            
  \<60               216(51.55%)            76(50.67%)                0.852
  ≥60                203(48.45%)            74(49.33%)                
  ALB(g/L)                                                            
  \<28               6(1.43%)               1(0.67%)                  0.743
  28-35              28(6.68%)              11(7.33%)                 
  ≥35                385(91.89%)            138(92.00%)               
  TBIL(umol/L)                                                        
  \<34.2             406(96.90%)            150(100.00%)              0.092
  34.2-51.3          6(1.43%)               0(0.00%)                  
  ≥51.3              7(1.67%)               0(0.00%)                  
  PT(sec)                                                             
  \<13.5             366(87.35%)            136(90.67%)               0.222
  ≥13.5              52(12.41%)             13(8.67%)                 
  CEA(ng/ml)                                                          
  \<5                358(85.44%)            125(83.33%)               0.496
  ≥5                 60(14.31%)             25(16.67%)                
  CA199(U/ml)                                                         
  \<35               278(66.35%)            97(64.67%)                0.942
  ≥35                127(30.31%)            45(30.00%)                

###### 

Univariate and multivariate cox hazards analysis of the primary cohort

                               Univariate analysis   Multivariate analysis                        
  ---------------------------- --------------------- ----------------------- -------------------- ---------
  Characteristic               HR (95% CI)           P                       HR (95% CI)          P
  Age                                                                                             
  \<57 vs. ≥57                 1.099(0.748-1.614)    0.632                                        
  Sex                                                                                             
  Male vs. Female              1.112(0.609-2.029)    0.729                                        
  BMI                                                                                             
  \<18.5 vs. 18.5-25 vs. ≥25   0.704(0.531-0.934)    0.015                   0.677(0.498-0.921)   0.013
  Family history                                                                                  
  No vs. Yes                   0.712(0.423-1.197)    0.199                                        
  Alcohol                                                                                         
  No vs. Yes                   0.933(0.623-1.396)    0.735                                        
  ECOG                                                                                            
  0-1 vs. 2                    o.547(0.076-3.924)    0.549                                        
  TNM stage                                                                                       
  Ⅰ vs. Ⅱ vs. Ⅲ-Ⅳ              2.273(1.813-2.851)    \<0.001                                      
  Tumor stage                                                                                     
  T1 vs. T2 vs. T3-T4          2.348(1.869-2.951)    \<0.001                 1.697(1.130-2.197)   \<0.001
  Node stage                                                                                      
  N0 vs. N1                    2.653(1.419-4.959)    0.002                   1.903(0.952-3.805)   0.069
  Metastasis stage                                                                                
  M0 vs. M1                    2.711(1.413-5.205)    0.003                   2.047(1.016-4.125)   0.045
  HBs Ag                                                                                          
  Negative vs. Positive        0.514(0.328-0.808)    0.004                   0.489(0.300-0.799)   0.004
  AST(U/L)                                                                                        
  \<40 vs. ≥40                 1.981(1.344-2.920)    0.001                   0.799(0.485-1.316)   0.379
  ALT(U/L)                                                                                        
  \<50 vs. ≥50                 1.225(0.827-1.813)    0.311                                        
  LDH(U/L)                                                                                        
  \<250 vs. ≥250               3.690(2.486-5.477)    \<0.001                 2.561(1.642-3.994)   \<0.001
  GGT(U/L)                                                                                        
  \<60 vs. ≥60                 3.206(2.106-4.878)    \<0.001                 2.551(1.569-4.149)   \<0.001
  ALB(g/L)                                                                                        
  \<28 vs. 28-35 vs. ≥35       0.315(0.222-0.447)    \<0.001                 2.549(1.647-3.946)   \<0.001
  TBIL(umol/L)                                                                                    
  \<34.2 vs. 34.2-51.3 ≥51.3   1.471(0.870-2.487)    0.150                                        
  PT(sec)                                                                                         
  \<13.5 vs. ≥13.5             1.930(1.196-3.114)    0.007                   0.938(0.538-1.636)   0.821
  CEA(ng/ml)                                                                                      
  \<5 vs. ≥5                   2.041(1.293-3.220)    0.002                   1.266(0.766-2.092)   0.358
  CA199(U/ml)                                                                                     
  \<35 vs. ≥35                 1.768(1.195-2.617)    0.004                   1.194(0.763-1.870)   0.438

###### 

The C-index of Eight Significant Risk Factors in the Primary Cohort

  Factors            C-index   95%CI
  ------------------ --------- -------------
  TNM stage          0.697     0.649-0.745
  BMI                0.560     0.518-0.602
  Tumor stage        0.701     0.653-0.749
  Metastasis stage   0.529     0.504-0.554
  HBs Ag             0.561     0.517-0.605
  LDH                0.630     0.584-0.676
  GGT                0.649     0.606-0.692
  ALB                0.574     0.537-0.611
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